Teleflex Incorporated (TFX) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call highlights strong revenue growth across segments and a strategic focus on innovation, with increased R&D investment. The company's guidance for 2026 shows optimism, particularly with planned divestitures and share repurchases. Despite some integration disruptions, the long-term outlook appears strong. The Q&A suggests analysts are generally satisfied, with no significant concerns raised. The company's refusal to provide quarterly guidance is offset by expected growth acceleration in the latter half of 2026. Overall, the strategic actions and financial outlook support a positive sentiment.
Key Financial Performance
Revenues Teleflex revenues were $548.3 million, up 32.3% year-over-year on a GAAP basis and an increase of 5.1% on a pro forma adjusted constant currency basis. The increase was driven by strong execution and some timing of orders in the surgical instrument portfolio.
Adjusted Earnings Per Share (EPS) First quarter adjusted EPS was $1.39, a 3.5% decrease year-over-year. The decrease was primarily due to tariffs, higher interest expense, partially offset by higher revenue and adjusted operating income, including the impact of the Vascular Intervention acquisition, higher R&D spending, and a lower share count.
Adjusted Gross Margin Adjusted gross margin was 61.4%, a 470 basis point decrease year-over-year. The decrease was primarily due to the adverse impact of tariffs, quality remediation charges associated with third-party supplier disruption, higher logistics and distribution costs, and the addition of the Vascular Intervention acquisition, which has a slightly lower gross margin than the corporate average.
Adjusted Operating Margin Adjusted operating margin was 18.1%, a 510 basis point decrease year-over-year. The decrease reflected gross margin pressure, higher operating expenses associated with the Vascular Intervention acquisition, and increased R&D investment, partially offset by the positive impact of foreign exchange rates.
Net Interest Expense Adjusted net interest expense totaled $24 million for the first quarter, compared to $17 million in the prior-year period. The increase was primarily due to borrowings used to finance the Vascular Intervention acquisition.
Tax Rate Adjusted tax rate for the first quarter of 2026 was 18.3%, compared to 16.4% in the prior year. The increase was primarily due to higher tax expense associated with stock-based compensation.
Cash Equivalents Cash equivalents and restricted cash equivalents balance was $329.6 million at the end of the first quarter, compared to $402.7 million as of year-end 2025.
Vascular Revenue Revenue increased 4.8% year-over-year to $236.8 million, primarily driven by growth in hemostatic products and the central venous and other access portfolio.
Interventional Revenue Revenue was $204.7 million, an increase of 3%. Performance was driven by intraosseous, right heart catheters, and complex catheters. Some disruption from integration and restructuring activities was noted, but momentum is expected to improve in the second half of the year.
Surgical Revenue Revenue was $106.8 million, an increase of 9.9%, primarily driven by strong performance in ligation clips and some timing of orders in the instrument portfolio. Instrument orders can be lumpy quarter-to-quarter, and some moderation of growth is anticipated in the second quarter.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Freesolve drug-eluting resorbable magnesium scaffold technology: Teleflex is advancing its clinical study for the Freesolve technology, which combines temporary scaffolding with drug delivery. Recruitment for the BIOMAG-II study in Europe is ahead of schedule, with a late 2027 data readout expected. Plans are in place to expand regulatory pathways, including initiating the BIOMAG-III pivotal trial in the U.S. during 2026.
Acquisition of BIOTRONIK's Vascular Intervention business: Completed in July 2025, this acquisition expanded Teleflex's coronary intervention portfolio and established a global footprint in the peripheral intervention market.
Restructuring plan: A multiyear restructuring plan was launched in Q1 2026, targeting $50 million in annual pretax cost savings by mid-2028. Savings are expected to accelerate in the second half of 2026.
Revenue and margin performance: Q1 2026 revenues were $548.3 million, up 32.3% year-over-year on a GAAP basis, with a pro forma adjusted constant currency growth of 5.1%. Adjusted operating margin was 18.1%.
Strategic divestitures: Teleflex is on track to sell its acute care, interventional urology, and OEM businesses by the second half of 2026. Proceeds will fund a $1 billion share repurchase program and reduce debt by $800 million.
Governance changes: Teleflex announced governance updates, including the nomination of Michael J. Tokich to the Board and the establishment of a new growth and operating committee. Leadership transitions include the appointment of Jason Weidman as President and CEO effective June 8, 2026.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Hurdles: Teleflex and the buyer of the acute care and interventional urology businesses received a second request for additional information from the U.S. Federal Trade Commission, which could delay the transaction closure.
Supply Chain Disruptions: Two third-party product suppliers initiated a recall for certain components included in vascular and interventional kits, leading to remediation costs and potential elevated back orders.
Integration Challenges: Disruption from the integration and restructuring activities of the Vascular Intervention business has impacted momentum, though improvement is expected in the second half of the year.
Cost Pressures: Higher logistics and distribution costs, tariffs, and quality remediation charges have negatively impacted gross margins.
Interest Expense: Increased net interest expense due to borrowings for the Vascular Intervention acquisition has added financial pressure.
Stranded Costs: Approximately $90 million in stranded costs from strategic divestitures are impacting the 2026 financial results.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Growth: Teleflex expects pro forma adjusted constant currency revenue growth for 2026 to be in the range of 4.5% to 5.5%. The company anticipates a mid-single-digit growth profile for its go-forward business.
Adjusted Earnings Per Share (EPS): The company projects adjusted EPS for 2026 to be in the range of $6.25 to $6.55. This guidance excludes the anticipated positive impact from the planned $1 billion share repurchase program and $800 million debt repayment, which are expected to significantly enhance EPS in 2027 and beyond.
Operating Margin: Teleflex expects its 2026 adjusted operating margin to be approximately 19%, reflecting $90 million in stranded costs from separation activities. The company anticipates a steady-state adjusted operating margin of approximately 23% in the future, driven by cost savings and revenue growth.
Capital Deployment: Teleflex plans to use proceeds from strategic divestitures to fund a $1 billion share repurchase program and reduce debt by $800 million. Share repurchases are expected to begin in the second quarter of 2026, ahead of the divestitures' completion.
Strategic Divestitures: The company expects to close the sales of its acute care, interventional urology, and OEM businesses in the second half of 2026, with the OEM transaction targeted for the third quarter. These divestitures are expected to generate $1.8 billion in net proceeds after tax.
Restructuring Plan: Teleflex has launched a multiyear restructuring plan aimed at achieving $50 million in annual pretax cost savings by mid-2028. Savings are expected to accelerate in the second half of 2026.
R&D Investment: The company plans to invest approximately 8% of sales in R&D during 2026, including advancing clinical studies for innovative technologies like the Freesolve drug-eluting resorbable magnesium scaffold technology.
Future Financial Profile: Teleflex anticipates significant improvements in margins, interest expense, and adjusted EPS starting in 2027, driven by the completion of divestitures, cost optimization, and capital deployment actions.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Share Repurchase Program: Teleflex plans to use proceeds from strategic divestitures to fund a share repurchase program of up to $1 billion. The company expects to begin opportunistic share repurchases in the open market during the second quarter of 2026, ahead of the previously anticipated timing of following the completion of the strategic divestitures. This reflects confidence in the business value and commitment to disciplined capital allocation and long-term shareholder value creation.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What are the expectations for second quarter revenue growth, and are you comfortable with the consensus estimate of $567 million?
A:The company is not providing quarterly revenue guidance. However, they expect accelerated growth in the second half of 2026. The CFO acknowledged potential risks such as recalls and instrument order timing but does not see these as problematic for the full year.
Q:What is causing the disruption in interventional sales integration?
A:The disruption is primarily due to the restructuring of territories following the integration of two sales forces.
Q:Why is there no change to the annual EPS guidance despite beating consensus estimates in Q1?
A:The company is maintaining its annual guidance as it is still early in the year, with many factors influencing guidance. They will update guidance as more information becomes available in the second quarter.
Q:Can you provide insights into growth across the three segments and which segments are driving growth?
A:Growth was balanced across segments. Vascular performed well with CVCs and hemostatics, Surgical saw strong performance with Hem-o-lok and instrument orders, and Interventional showed growth in complex catheters and DCBs. Interventional is expected to be the largest growth driver in the long term.
Q:What is the impact of cost inflation on manufacturing and freight, and are there any margin headwinds?
A:There is no significant impact from cost inflation. While L&D costs have increased due to the Iran conflict, the company has programs in place to offset these costs, keeping risks within the guidance range for operating margins.
Q:What is the role of the new Board committee, and what are the expectations for the BIOMAG trials?
A:The new Board committee will focus on growth plans and monitoring their execution. For BIOMAG-II in Europe, enrollment is ahead of schedule, with data expected in 2027. BIOMAG-III in the U.S. will start in 2026, with data likely available around 2030.
Q:Why was Jason chosen as the new CEO, and when can we expect to hear about the company's strategic vision?
A:Jason was chosen for his alignment with the company's culture, proven growth leadership, ability to manage complexity, and global perspective. The company has no immediate plans for an Investor Day but will update stakeholders after Jason gets acclimated.
Q:What is the directional outlook for 2027 sales and operating margins?
A:The company has not provided 2027 sales guidance. However, they indicated a normalized operating margin of 23% excluding stranded costs, with opportunities for further improvement as the company grows.
Q:Was the company approached about a transaction, and what is the timing for the $1 billion share repurchase program?
A:The company does not comment on market rumors or speculation. The share repurchase program may extend into 2027 due to its size and volume limits.
Q:How much of the $90 million in stranded costs has flowed through in Q1, and what is the quarterly cadence?
A:The stranded costs are conceptual and not specifically identified. They are expected to flow through ratably throughout the year.
Q:What caused Interventional to grow below target in Q1, and what is the outlook for Surgical?
A:Interventional's slower growth was due to sales force integration disruption and restructuring. Surgical performed well across its portfolio, including Hem-o-lok and bariatric staplers, with strong growth expected to continue.
Q:What is the company's approach to shareholder value creation and the impact of tariffs on guidance?
A:The Board is open to considering all avenues for long-term value creation. Tariff refunds would be upside to guidance, with $33 million in tariffs included in the full-year guidance.
Q:Review of Unclear Management Responses
A:Management avoided directly addressing whether the company was approached about a transaction, referring instead to prior public statements. Additionally, they did not provide specific guidance for 2027 sales or detailed timing for the $1 billion share repurchase program.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Interim President
MSA arrangement
OEM
President CEO
RD investment
TSA MSA
Vascular Intervention
acquisition
action
acute care
business
care urology
debt
end
factor
forma currency
governance
impact TSA
increase
interest expense
margin
order
proceeds divestiture
profile
remediation
saving
share repurchase
shareholder value
tax
term
track
transaction
TFX Transcript
Teleflex Incorporated (TFX) Q1 2026 Earnings Call Transcript
Positive5-7
The earnings call highlights strong revenue growth across segments and a strategic focus on innovation, with increased R&D investment. The company's guidance for 2026 shows optimism, particularly with planned divestitures and share repurchases. Despite some integration disruptions, the long-term outlook appears strong. The Q&A suggests analysts are generally satisfied, with no significant concerns raised. The company's refusal to provide quarterly guidance is offset by expected growth acceleration in the latter half of 2026. Overall, the strategic actions and financial outlook support a positive sentiment.
Teleflex Incorporated (TFX) Q4 2025 Earnings Call Transcript
Unknown2-26
The earnings call presents mixed signals: a positive shareholder return plan with significant share repurchases, strong EPS growth, and successful product launches. However, concerns arise from the reduced revenue guidance, increased expenses, and unclear future growth plans. The Q&A session highlighted uncertainties in management's responses and potential risks from tariff impacts. These mixed factors balance each other out, leading to a neutral sentiment prediction for stock price movement.
Teleflex Incorporated (TFX) Presents at Jefferies London Healthcare Conference 2025 Transcript
Neutral11-18
Teleflex Incorporated (TFX) Q3 2025 Earnings Call Transcript
Positive11-6
The earnings call highlights several positive factors: increased revenue growth guidance, improved adjusted gross margins, and strong performance in the Vascular Intervention business. The Q&A session further supports this with positive insights on market share growth and successful integration of acquisitions. Although cash flow from operations decreased, the overall financial outlook and strategic plans, including a focus on maximizing shareholder value through a potential sale, suggest a positive sentiment. The upward revision of guidance and strong market performance indicate a likely positive stock price movement in the short term.
TFX Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
